Experts Tackle Key Challenges in Dermatology Research

Vial’s newly launched contract research organization (CRO) addressed ways to surmount some of the biggest obstacles blocking increased speed and quality of clinical trials with an advisory board meeting at Maui Derm for Dermatologists 2022.

Identifying and solving the biggest challenges in dermatology research will be a dual focus of Vial's newly announced contract research organization (CRO) advisory board which will meet in conjunction with Maui Derm for Dermatologists 2022, January 24 to 28, 2022 in Wailea, Hawaii.

Also under discussion will be key issues such as growth drivers for practices and dermatology research sites as well as development of initiatives to engage the entire dermatology community, including research sponsors, KOLs, and heads of leading research sites in answering unmet needs in clinical research.

Leon Kircik, MD, FAAD, will cohost the advisory boad meeting with Vial. He is founder and medical director of DermResearch and Physicians Skin Care, both in Louisville, Kentucky, and clinical professor of dermatology at Indiana University Medical Center in Indianapolis, Indiana, and at Icahn School of Medicine in New York City.

Representing Vial at the conference will be the company's CRO executive team: Betsey Zbyszynski, head of clinical operations, Jason Shuris, head of sales, Janet DuBois, MD, medical director, Justin Withers, head of dermatology, and Mamta Hunt, head of quality.

They will be joined by the heads of leading research sites across the country to discuss and collaborate on the role Vial dermatology CRO could play in tackling challenges in the specialty, especially in regard to increasing the speed and quality of clinical trials, and growing dermatology research sites.

Launched in mid-January, 2022, with the tagline, "The CRO built for sponsors," the Vial Dermatology CRO is powered by the Vial Clinical Network of more than 35 dermatology clinics throughout the United States.

Feedback from these leading clinicians will form the basis of a whitepaper to be published by Vial, whose network has contributed to more than 150 Phase I through Phase IV trials across common medical dermatology indications.